Response to the comment by Dr Yarlas.
作者信息
Aimo Alberto
机构信息
Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
出版信息
Eur J Clin Invest. 2021 Nov;51(11):e13652. doi: 10.1111/eci.13652. Epub 2021 Jul 28.
Abstract
摘要
相似文献
1
Response to the comment by Dr Yarlas.对亚拉斯博士评论的回应。
Eur J Clin Invest. 2021 Nov;51(11):e13652. doi: 10.1111/eci.13652. Epub 2021 Jul 28.
2
Comment on the comment by Dr. Marino and Dr. Frilot on "Proposed test for detection of nonlinear response in biological preparations exposed to RF energy".
Bioelectromagnetics. 2003 Sep;24(6):440-1; discussion 442-3. doi: 10.1002/bem.10144.
3
[Erratum to: Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration].[勘误：慢性下腰痛中的阿片类药物。对至少持续4周的随机安慰剂对照研究中的疗效、耐受性和安全性进行的系统评价和荟萃分析]
Schmerz. 2015 Jul;29(3):308. doi: 10.1007/s00482-015-0010-8.
4
Response to Dr Krous and Dr Byard's comment regarding EHD paper.对克劳斯博士和拜尔德博士关于EHD论文评论的回应。
Early Hum Dev. 2008 Jul;84(7):421. doi: 10.1016/j.earlhumdev.2007.11.001. Epub 2008 Jan 14.
5
Last word.
J Prim Prev. 1985 Jun;5(4):310-2. doi: 10.1007/BF01324559.
6
Editorial Comment: Heterogeneity of Bone Marrow Stromal Cells Editorial Comment on Dr. Waller's Paper.编辑评论：骨髓基质细胞的异质性 对沃勒博士论文的编辑评论
Hematology. 1999;4(1):45-6. doi: 10.1080/10245332.1999.11746429.
7
Editorial comment from Dr Catena, Dr Colussi and Dr Sechi to preoperative masked renal damage in japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy.卡泰纳博士、科卢西博士和塞奇博士对日本原发性醛固酮增多症患者术前隐匿性肾损伤的编辑评论：肾上腺切除术后慢性肾脏病表现的预测因素识别。
Int J Urol. 2013 Jul;20(7):692-3. doi: 10.1111/iju.12040. Epub 2012 Dec 6.
8
Response to Dr. Murphy and Dr. Ferguson regarding comment on our paper: retrospective evaluation of antimicrobial prophylaxis in prevention of surgical site infection in the pediatric population.针对墨菲博士和弗格森博士对我们论文《儿科人群手术部位感染预防中抗菌药物预防的回顾性评估》评论的回复
Paediatr Anaesth. 2015 Feb;25(2):218. doi: 10.1111/pan.12598.
9
Medical ethics: on Dr. Davant's article and Dr. Alexander's comment.医学伦理学：关于达万特博士的文章及亚历山大博士的评论。
N C Med J. 1989 Oct;50(10):586-7.
10
Response to Editorial Comment from Dr Cantiello and Dr Damiano to Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review.
Int J Urol. 2015 Nov;22(11):993. doi: 10.1111/iju.12945. Epub 2015 Sep 7.
本文引用的文献
1
Management of complications of cardiac amyloidosis: 10 questions and answers.心脏淀粉样变性并发症的管理：10 个问答。
Eur J Prev Cardiol. 2021 Aug 9;28(9):1000-1005. doi: 10.1177/2047487320920756. Epub 2020 Apr 16.
2
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis.淀粉样变转甲状腺素蛋白（ATTR）淀粉样变性的生活质量评估。
Eur J Clin Invest. 2021 Nov;51(11):e13598. doi: 10.1111/eci.13598. Epub 2021 May 22.
3
Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.遗传性转甲状腺素蛋白淀粉样变多发性神经病损伤测量指标的发展：从神经病变损害评分（NIS）到改良神经病变损害评分（mNIS）+7。
J Neurol Sci. 2019 Oct 15;405:116424. doi: 10.1016/j.jns.2019.116424. Epub 2019 Aug 8.
4
Treatment of cardiac transthyretin amyloidosis: an update.心脏转甲状腺素淀粉样变性的治疗：最新进展。
Eur Heart J. 2019 Dec 1;40(45):3699-3706. doi: 10.1093/eurheartj/ehz298.
5
Recent advances in the treatment of familial amyloid polyneuropathy.家族性淀粉样多神经病治疗的最新进展。
Ther Adv Neurol Disord. 2013 Mar;6(2):129-39. doi: 10.1177/1756285612470192.
Zotero 插件